NCT05582876View on ClinicalTrials.gov

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Prostate Cancer
Interventions
RADIATION

Radiopharmaceutical 68Ga-PSMA-11 PET/CT

The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.

Trial Locations (7)

15-027

RECRUITING

Białystok Oncology Center Maria Skłodowska-Curie, Bialystok

15-276

RECRUITING

University Clinical Hospital in Białystok, Bialystok

15-471

NOT_YET_RECRUITING

Independent Public Health Care Center of the Ministry of Internal Affairs and Administration in Białystok, Bialystok

15-540

RECRUITING

Laboratory of Molecular Imaging and Technology Development, Bialystok

85-796

RECRUITING

Oncology Center named after prof. F. Łukaszczyk in Bydgoszcz, Bydgoszcz

93-513

NOT_YET_RECRUITING

Provincial Multidisciplinary Center of Oncology and Traumatology named after M. Copernicus University in Łódź, Lodz

20-090

RECRUITING

Center of Oncology of the Lublin Region St. Jana z Dukli, Lublin

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

lead

Medical University of Bialystok

OTHER

NCT05582876 - Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter